BioSpace News Archive

Eli Lilly and Company (NYSE: LLY) and Direct Relief today announced a new initiative to expand access to medicines in low- and middle-income countries by boosting cold chain capacity in 17 countries.

A biosimilar medicine is developed to be highly similar to an existing biological, or reference, product.

MDimune Inc., a Korean biotech company developing BioDrone™ platform technology based on cell-derived vesicles (CDVs), announces funding of two research projects focusing on next-generation drug delivery and novel therapeutics.

In many ways, our intestines serve as the front gate between our bodies and the world around us. They help digest our food and absorb our medications. They send alarm signals when harmful bacteria, viruses, and allergens invade.

DiscGenics, Inc. today announced the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to Injectable Disc Cell Therapy (IDCT or rebonuputemcel), an injectable, allogeneic discogenic progenitor cell therapy for the treatment of symptomatic lumbar degenerative disc disease (DDD).

The researchers at NYU Grossman School of Medicine and the University of Toronto who designed the tool say it promises to accelerate the development of gene therapies on a large scale.

Vista.ai, a pioneer and leader in automated MRI solutions, today announced results from a clinical adaptation study on the company’s One Click MRI™ software, led by Dr. Raymond Kwong, Director, Cardiac Magnetic Resonance Imaging for Harvard-affiliated Brigham and Women’s Hospital.

Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has expanded its fluoxetine product family with the launch of Fluoxetine Oral Solution, USP, 20 mg/5 mL.

23andMe Holding Co. announced that it will report financial results for the fiscal year 2023 third quarter after the market closes on Wednesday, February 8, 2023.

Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, Jan. 31, 2023, after the close of the U.S. financial markets.